Application of next‐generation sequencing to improve cancer management: A review of the clinical effectiveness and cost‐effectiveness
- 8 February 2018
- journal article
- review article
- Published by Wiley in Clinical Genetics
- Vol. 93 (3), 533-544
- https://doi.org/10.1111/cge.13199
Abstract
Uptake of Next-Generation Sequencing (NGS) has increased dramatically due to significant cost reductions and broader community acceptance of NGS. To systematically review the evidence on both the clinical effectiveness and the cost-effectiveness of applying NGS to cancer care. A systematic search for full-length original research articles on the clinical effectiveness and cost-effectiveness of NGS in MEDLINE and EMBASE. Articles that focussed on cancer care and involved the application of NGS were included for the review of clinical effectiveness. For the cost-effectiveness review, we only included the articles with economic evaluations of NGS in cancer care. We report the rate of successfully detecting mutations from the clinical studies. The Incremental Cost-Effectiveness Ratio and sensitivity analysis outcomes are reported for the cost-effectiveness articles. Fifty-six articles reported that sequencing patient samples using targeted gene panels, and 83% of the successfully sequenced patients harboured at least one mutation. Only six studies reported on the cost-effectiveness of the application of NGS in cancer care. NGS is an effective tool for identifying mutation in cancer patients. However, more rigorous cost-effectiveness studies of NGS applied to cancer management are needed to determine whether NGS can improve patient outcomes cost-effectively.Keywords
This publication has 45 references indexed in Scilit:
- The role of personalized medicine in metastatic colorectal cancer: an evolving landscapeTherapeutic Advances in Gastroenterology, 2013
- Molecular diagnostics of a single multifocal non-small cell lung cancer case using targeted next generation sequencingVirchows Archiv, 2012
- QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy StudiesAnnals of Internal Medicine, 2011
- Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic ProfilingJournal of Clinical Oncology, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With CetuximabJAMA, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- The cancer genomeNature, 2009
- Good Practice Guidelines for Decision-Analytic Modelling in Health Technology AssessmentPharmacoEconomics, 2006
- A census of human cancer genesNature Reviews Cancer, 2004